[HTML][HTML] Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer
M Luu, Z Riester, A Baldrich, N Reichardt… - Nature …, 2021 - nature.com
Emerging data demonstrate that the activity of immune cells can be modulated by microbial
molecules. Here, we show that the short-chain fatty acids (SCFAs) pentanoate and butyrate …
molecules. Here, we show that the short-chain fatty acids (SCFAs) pentanoate and butyrate …
Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling
V Fleming, X Hu, C Weller, R Weber, C Groth, Z Riester… - Cancer Research, 2019 - AACR
Tumor cell–derived extracellular vesicles (EV) convert normal myeloid cells into myeloid-
derived suppressor cells (MDSC), inhibiting antitumor immune responses. Here, we show …
derived suppressor cells (MDSC), inhibiting antitumor immune responses. Here, we show …
[HTML][HTML] IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
R Weber, Z Riester, L Hüser, C Sticht… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Myeloid-derived suppressor cells (MDSC) play a major role in the
immunosuppressive melanoma microenvironment. They are generated under chronic …
immunosuppressive melanoma microenvironment. They are generated under chronic …
New targets and technologies for CAR-T cells
F Freitag, M Maucher, Z Riester… - Current Opinion in …, 2020 - journals.lww.com
Summary CD19 CAR-T cell therapy is an approved treatment for B-cell leukemia and-
lymphoma and considering the current 'target and technology'pipeline, we anticipate that …
lymphoma and considering the current 'target and technology'pipeline, we anticipate that …
[HTML][HTML] P836: ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA
A Bielowski, T Kilian, SRC Vera-Cruz, Z Riester… - …, 2023 - journals.lww.com
Background: The recent approval of BCMA-targeting CAR-T cell products for
refractory/relapsed multiple myeloma (MM) has reframed the landscape of MM therapy by …
refractory/relapsed multiple myeloma (MM) has reframed the landscape of MM therapy by …
P-004: Pharmacological inhibition and depletion strategies for SLAMF7 CAR-T cells in multiple myeloma
S Danhof, T Kilian, A Schmidt, Z Riester… - … Myeloma and Leukemia, 2021 - Elsevier
Background Recent and soon-to-expect approvals have significantly increased the number
of patients treated with CAR-T cells and clinical responses can be very impressive …
of patients treated with CAR-T cells and clinical responses can be very impressive …
Anti-P329G-CAR-T cells as a novel universal CAR-T cell platform
D Darowski, C Jost, Z Riester, M Benmebarek… - Cancer Research, 2020 - AACR
Introduction: In the rapidly growing field of chimeric antigen receptor (CAR) engineered T
cells new approaches aim to make CAR-T cell therapy safer and more effective. Recent …
cells new approaches aim to make CAR-T cell therapy safer and more effective. Recent …
[CITATION][C] Microbial short-chain fatty acids enhance CD8+ T cell-mediated cancer immunotherapy
M Luu, Z Riester, A Baldrich… - EUROPEAN …, 2021 - … ST, HOBOKEN 07030-5774, NJ USA